Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novartis receives new EU approval for Afinitor

Novartis receives new EU approval for Afinitor

2nd June 2016

Novartis has announced that its drug Afinitor has been approved by the European Commission in a new indication.

The decision allows Afinitor tablets to be used in the treatment of unresectable or metastatic well-differentiated nonfunctional neuroendocrine tumours (NETs) of gastrointestinal or lung origin in adults with progressive disease.

It becomes the first approved therapy in Europe for this type of lung tumour, and one of very few treatment options available for this type of gastrointestinal tumours of this kind.

The EU approval was based on positive data from the pivotal phase III trial RADIANT-4, which demonstrated the drug's positive impact on minimising disease progression and improving survival rates.

Bruno Strigini, president of Novartis Oncology, said: "As a company that has long been dedicated to advancing care for NET patients, we are pleased that this latest milestone makes Afinitor available to patients in the EU who previously had few or no approved treatment options."

Afinitor is also approved in Europe for the treatment of NETs of pancreatic origin, as well as for advanced renal cell carcinoma and certain breast cancer types.ADNFCR-8000103-ID-801819604-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.